BIOMÉRIEUX |
Market Closed -
Other stock markets
|
After market 04:00:00 pm | |||
| 102.3 EUR | +0.79% |
|
102.4 | +0.10% |
| Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
| Apr. 26 | BIOMÉRIEUX : Berenberg raises its target | CF |
Presenter SpeechPierre Boulud (Executives)So good morning, everybody. I'm Pierre Boulud. I'm t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-05-22
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
101.5
EUR
Average target price
112.8
EUR
Spread / Average Target
+11.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.69% | 12.8B | |
| -7.57% | 7.61B | |
| +3.22% | 5.41B | |
| +0.93% | 4.51B | |
| +8.48% | 4.49B | |
| +9.21% | 2.73B | |
| -13.87% | 2.02B | |
| -11.63% | 1.73B | |
| +3.45% | 1.64B | |
| -5.65% | 1.53B |
- Stock Market
- Equities
- BIM Stock
- News bioMérieux
- Transcript : BioMérieux S.A. - Analyst/Investor Day
